Article
Immunology
Qian Chen, Xiaoling Shang, Ni Liu, Xinchun Ma, Wenfei Han, Xiuwen Wang, Yanguo Liu
Summary: The study found that patients with major EGFR mutations had poorer responses to ICIs compared to patients with rare EGFR mutations. EGFR-mutated patients with lower PD-L1 expression tended to have longer overall survival after receiving ICIs. Heavily treated patients with more than three prior lines of therapy had significantly shorter progression-free survival and overall survival, as well as a lower objective response rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biology
Xiaolong Tang, Lizhi Cheng, Guo Li, Yong-Ming Yan, Fengting Su, Dan-Ling Huang, Shuping Zhang, Zuojun Liu, Minxian Qian, Ji Li, Yong-Xian Cheng, Baohua Liu
Summary: The small molecule compound D6 demonstrates promising efficacy in treating EGFR-TKI resistant NSCLC by targeting the protein-protein interaction between HSP90 and T790M-EGFR, offering a potential alternative strategy to overcome drug resistance.
COMMUNICATIONS BIOLOGY
(2021)
Article
Multidisciplinary Sciences
Tereza Vaclova, Ursula Grazini, Lewis Ward, Daniel O'Neill, Aleksandra Markovets, Xiangning Huang, Juliann Chmielecki, Ryan Hartmaier, Kenneth S. Thress, Paul D. Smith, J. Carl Barrett, Julian Downward, Elza C. de Bruin
Summary: T790M subclonality is associated with poorer response to osimertinib and shorter progression-free survival, likely due to co-occurring PIK3CA alterations which can be targeted by PI3K pathway inhibitors.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Petr Makhov, Igor Bychkov, Bulat Faezov, Alexander Deneka, Alexander Kudinov, Emmanuelle Nicolas, Rohan Brebion, Eleanor Avril, Kathy Q. Cai, Leonid V. Kharin, Mark Voloshin, Elena Frantsiyants, Nikolay Karnaukhov, Oleg I. Kit, Iuliia Topchu, Rushaniya Fazliyeva, Anna S. Nikonova, Ilya G. Serebriiskii, Hossein Borghaei, Martin Edelman, Essel Dulaimi, Erica A. Golemis, Yanis Boumber
Summary: MSI2 regulates EGFR protein expression in non-small cell lung cancer, and depletion of MSI2 can affect proliferation of EGFR(mut) cells and response to EGFR-targeting drugs, suggesting inhibition of MSI2 could be clinically valuable in EGFR(mut) NSCLC.
Article
Biochemistry & Molecular Biology
Byoung Chul Cho, Dong-Wan Kim, Alexander I. Spira, Jorge E. Gomez, Eric B. Haura, Sang-We Kim, Rachel E. Sanborn, Eun Kyung Cho, Ki Hyeong Lee, Anna Minchom, Jong-Seok Lee, Ji-Youn Han, Misako Nagasaka, Joshua K. Sabari, Sai-Hong Ignatius Ou, Patricia Lorenzini, Joshua M. Bauml, Joshua C. Curtin, Amy Roshak, Grace Gao, John Xie, Meena Thayu, Roland E. Knoblauch, Keunchil Park
Summary: This study evaluated the potential of combining amivantamab and lazertinib in patients with EGFR-mutated NSCLC. The results showed that this combination therapy had improved anti-tumor activity in some patients, with a safety profile similar to monotherapy.
Article
Pharmacology & Pharmacy
Balazs Gyorffy
Summary: This study established a comprehensive database of transcriptome-level data for lung cancer, which can be used to identify and rank the most promising biomarkers and therapeutic targets for different subtypes of lung cancer.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Oncology
Afeez Adekunle Ishola, Chian-Shiu Chien, Yi-Ping Yang, Yueh Chien, Aliaksandr A. Yarmishyn, Ping-Hsing Tsai, Jerry Chieh-Yu Chen, Po-Kuei Hsu, Yung-Hung Luo, Yuh-Min Chen, Kung-Hou Liang, Yuan-Tzu Lan, Teh-Ia Huo, Hsin- Ma, Ming-Teh Chen, Mong-Lien Wang, Shih-Hwa Chiou
Summary: Lung cancers, particularly non-small cell lung cancers, have a poor prognosis. A circular noncoding RNA called C190 has been identified as a negative prognostic biomarker for lung cancer, and this study explores its mechanistic function and potential as a therapeutic target for NSCLC.
Article
Cell Biology
Xiao-Wei Zhang, Lin Li, Wen-Qian Hu, Ming-Ning Hu, Yan Tao, Hui Hu, Xiao-Kang Miao, Wen-Le Yang, Qiong Zhu, Ling-Yun Mou
Summary: This study reveals that G protein-coupled receptor neurokinin-1 (NK1R) is significantly upregulated in lung cancer samples and is associated with advanced clinical stages and poor prognosis. NK1R co-expresses with epidermal growth factor receptor (EGFR) and interacts with it in tumor cells. Activation of NK1R promotes lung cancer cell proliferation and migration through EGFR signaling pathways. Inhibition of NK1R suppresses cell proliferation and migration, and knockdown of NK1R slows down tumor growth. The presence of a selective NK1R antagonist enhances the sensitivity of lung cancer cells to specific drugs.
CELL DEATH & DISEASE
(2022)
Review
Biochemistry & Molecular Biology
Tohru Ohmori, Toshimitsu Yamaoka, Koichi Ando, Sojiro Kusumoto, Yasunari Kishino, Ryou Manabe, Hironori Sagara
Summary: The tyrosine kinase activity of EGFR plays critical roles in cell proliferation, regeneration, tumorigenesis, and anticancer resistance. EGFR-TKI-induced ILD can be tolerable and manageable, but may also result in serious lung injury, particularly in the presence of specific risk factors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Multidisciplinary Sciences
Dongliang Bian, Liangdong Sun, Junjie Hu, Liang Duan, Haoran Xia, Xinsheng Zhu, Fenghuan Sun, Lele Zhang, Huansha Yu, Yicheng Xiong, Zhida Huang, Deping Zhao, Nan Song, Jie Yang, Xiao Bao, Wei Wu, Jie Huang, Wenxin He, Yuming Zhu, Gening Jiang, Peng Zhang
Summary: This study aimed to assess the feasibility of neoadjuvant Afatinib treatment for stage III NSCLC patients. The results showed that Afatinib improved the objective response rate (ORR) in NSCLC patients and caused dynamic changes in the tumor microenvironment.
NATURE COMMUNICATIONS
(2023)
Letter
Oncology
Si-Yang Maggie Liu, Cunte Chen, Yi-Kai Zhang, Wen-Zhao Zhong, Yi-Long Wu, Si-Yang Liu, Yangqiu Li
Summary: This study identified specific TCR sequences that can predict prognosis and favorable outcomes in EGFR-mutant NSCLC patients treated with adjuvant EGFR-TKI.
BIOMARKER RESEARCH
(2023)
Article
Oncology
Woraseth Saifon, Insee Sensorn, Narumol Trachu, Songporn Oranratnachai, Angkana Charoenyingwattana, Chakkaphan Runcharoen, Nanamon Monnamo, Warawut Sukkasem, Pimpin Inchareon, Thitiporn Suwatanapongched, Phichai Chansriwong, Touch Ativitavas, Ravat Panvichian, Wasun Chantratita, Thanyanan Reungwetwattana
Summary: This study explores the correlation between gastrointestinal microbiota profile and clinical outcomes in Thai advanced non-small cell lung cancer (NSCLC) patients according to epidermal growth factor receptor (EGFR) status. The results show that the microbiota profile is associated with EGFR status and treatment response, but the correlation between gastrointestinal microbiota profile and treatment response is not significant. However, there is a significant difference in beta diversity of the microbiota according to the severity of adverse events. This study highlights the potential predictive utility of the gastrointestinal microbiota for lung cancer carcinogenesis.
Review
Oncology
Catherine B. Meador, Lecia Sequist, Zofia Piotrowska
Summary: EGFR ins20 mutations, occurring in approximately 10% of EGFR-activating mutations, have historically shown reduced sensitivity to early-generation EGFR TKIs. However, recent advancements in scientific understanding and clinical detection techniques have improved our ability to develop effective therapies for this subset of EGFR-mutant NSCLC.
Article
Immunology
Zhixing Hao, Mingjie Lin, Feng Du, Zhongwei Xin, Dang Wu, Qun Yu, Yimin Wu, Zhouyu Zhu, Wenshan Li, Yongyuan Chen, Xiaoke Chen, Ying Chai, Shenghang Jin, Pin Wu
Summary: This study identified systemic immune dysregulation in the peripheral blood of early NSCLC patients and demonstrated the correlation between these dysregulations and clinical features. These findings suggest that systemic immune dysregulation is involved in cancer development and may be a promising candidate for high-risk screening and treatment strategies for early NSCLC.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Nidhi Saini, Ajmer Singh Grewal, Viney Lather, Suresh Kumar Gahlawat
Summary: Phytochemicals contribute to protection and interaction processes by acting as antioxidants, anti-mutagens, anticarcinogens, and antimicrobial agents. In this study, sanguinarine was found to be the most potent inhibitor of epidermal growth factor receptor (EGFR) compared to erlotinib. Other alkaloids also showed potent inhibition against EGFR, but their stability with EGFR varied. Out of the 31 alkaloids subjected to ADMET prediction, 29 alkaloids followed Lipinski's rule of five and were predicted to have high bioavailability, low toxicity, and ease of synthesis.
CHEMICO-BIOLOGICAL INTERACTIONS
(2022)